Why the study?
Does dual therapy with oral anticoagulant and single antiplatelet therapy improve safety and efficacy compared to triple therapy in patients requiring long-term anticoagulation and undergoing percutaneous coronary intervention?
Does dual therapy with oral anticoagulant and single antiplatelet therapy improve safety and efficacy compared to triple therapy in patients requiring long-term anticoagulation and undergoing percutaneous coronary intervention?
This review summarizes emerging evidence on the safety and efficacy of dual versus triple antithrombotic therapy in patients requiring long-term anticoagulation who undergo PCI.
Management of patients on long-term anticoagulation requiring percutaneous coronary intervention is challenging. Triple therapy with oral anticoagulant and dual antiplatelet therapy is the standard of care. However, there is no strong evidence to support this strategy. There is emerging data regarding the safety and efficacy of dual therapy with oral anticoagulant and single antiplatelet therapy in these patients. In this comprehensive review we highlight available evidence regarding various antithrombotic regimens' efficacy and safety in patient with coronary artery disease undergoing percutaneous coronary intervention with long-term anticoagulation therapy requirements.
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2018) conducted a review in Coronary artery disease requiring long-term anticoagulation and percutaneous coronary intervention. Dual therapy (oral anticoagulant and single antiplatelet therapy) vs. Triple therapy (oral anticoagulant and dual antiplatelet therapy) was evaluated on Efficacy and safety.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: